Record year with revenue up 14.3% and EBITDA up 91%, driven by focus on sexual health and own brands. Q4 saw 23.1% sales growth and a 10.9% EBITDA margin. Strong cash flow and balance sheet support a proposed 1.00 SEK per share dividend.Original document: Vuxen Group AB [VUXEN] Interim report — Jun…
Record year with revenue up 14.3% and EBITDA up 91%, driven by focus on sexual health and own brands. Q4 saw 23.1% sales growth and a 10.9% EBITDA margin. Strong cash flow and balance sheet support a proposed 1.00 SEK per share dividend.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
